Printer Friendly

Shionogi Got Approval of Additional Indication of INTUNIV in Japan for Treatment of Adult ADHD.

ENPNewswire-June 19, 2019--Shionogi Got Approval of Additional Indication of INTUNIV in Japan for Treatment of Adult ADHD

(C)2019 ENPublishing - http://www.enpublishing.co.uk

Release date- 18062019 - Osaka - Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: Isao Teshirogi, Ph.D.; hereafter 'Shionogi') today announced the approval for INTUNIV (guanfacine hydrochloride) for the treatment of attention deficit hyperactivity disorder (ADHD) with additional indication in adult patients.

INTUNIV is a 'selective 2A adrenergic receptor agonist', firstly approved as a drug for ADHD with this mechanism of action, and INTUNIV is a non-central nervous system stimulant that is to be administered once daily and has been approved as a drug for ADHD in pediatric patients (6 to 17 years old) in 36 countries including Japan (as of March 2018). In Japan, Shionogi launched INTUNIV for indication of ADHD in pediatric patients on May 2017.

Shionogi conducted the clinical studies of INTUNIV in adult ADHD patients (18 years old and over) in Japan first in the world. INTUNIV demonstrated a statistically significant improvement compared with placebo in the primary endpoint of ADHD evaluation scale. INTUNIV also demonstrated statistically significant superior efficacy compared with placebo in the clinically important secondary endpoint of the clinical global impression improvement scale (CGI-I). Additionally, INTUNIV demonstrated favorable safety and efficacy profile in long-term treatment for 1 year at longest. Shionogi filed for partial change approval for adult patients based on the abovementioned data.

Dosage & Patient under 18 years old: (the underlined part is added from June 18,2019) Administration: In general, start administrating this drug 1mg daily (as guanfacine) to patients under 18 years old with the body weight under 50kg, and 2mg daily to those with body weight 50kg or over; Increase the dose by 1mg each at intervals of one week or longer up to the maintenance dose. The dosage should be adjusted depending on the symptoms. The drug should be administered orally once daily. Patients 18 years or older:

In general, start administering this drug 2mg daily to those who are 18 years or older; Increase the dose by 1mg each at intervals of one week or longer up to the maintenance dose from 4 to 6mg daily. The dosage should be adjusted depending on the symptoms. However, the maxim dose should not exceed 6mg per day. The drug should be administered orally once daily.

NHI price: 407.20 yen per INTUNIV Tablet 1mg 537.50 yen per INTUNIV Tablet 3mg

Forward Looking Statement

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Productrisks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Contact:

Tel: +81-6-6209-7885

[Editorial queries for this story should be sent to newswire@enpublishing.co.uk]

((Distributed via M2 Communications - http://www.m2.com))
COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:ENP Newswire
Geographic Code:9JAPA
Date:Jun 19, 2019
Words:611
Previous Article:Shionogi & Co., Ltd. - Announcement about the Adjustment of the Conversion Value for Euro-Yen Denominated Convertible Bonds Maturing in 2019.
Next Article:Shionogi to Present Cefiderocol and COT-143 Data at American Society for Microbiology Microbe 2019 Meeting.
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |